A new trading day began on Tuesday, with Standard BioTools Inc (NASDAQ: LAB) stock price up 7.95% from the previous day of trading, before settling in for the closing price of $1.51. LAB’s price has ranged from $0.92 to $2.14 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 11.61%. Meanwhile, its annual earnings per share averaged 60.16%. With a float of $368.61 million, this company’s outstanding shares have now reached $383.61 million.
Standard BioTools Inc (LAB) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of Standard BioTools Inc is 4.15%, while institutional ownership is 76.48%. The most recent insider transaction that took place on Dec 04 ’25, was worth 217,020. In this transaction Director of this company bought 150,000 shares at a rate of $1.45, taking the stock ownership to the 72,100,000 shares. Before that another transaction happened on Dec 02 ’25, when Company’s Director bought 125,000 for $1.42, making the entire transaction worth $177,512. This insider now owns 71,875,000 shares in total.
Standard BioTools Inc (LAB) Performance Highlights and Predictions
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.05 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 60.16% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 42.89% during the next five years compared to 11.61% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
Here are Standard BioTools Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.14. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.34, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.12 in one year’s time.
